Cochrane · systematic review · CD006918
Risperidone versus placebo for schizophrenia
Rattehalli, RD, Zhao, S, Li, BG, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 3 · 37.5%Low 4 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRISPERIDONE compared to PLACEBO for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: no clinically significant response in psychotic symptoms (defined by various scale total score change) ‐ short term (up to 12 weeks) ‐ defined by PANSS/BPRS <20% decline RISPERIDONE vs PLACEBO | RR 0.64 [0.52, 0.78] | 6 studies · 864 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
Leaving the study early ‐ short term (up to 12 weeks) ‐ any reason RISPERIDONE vs PLACEBO | RR 0.69 [0.62, 0.78] | 12 studies · 2261 participants | Low Downgraded: risk of bias, publication bias |
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) RISPERIDONE vs PLACEBO | RR 0.69 [0.57, 0.83] | 4 studies · 594 participants | Very low Downgraded: risk of bias, inconsistency, publication bias |
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS RISPERIDONE vs PLACEBO | RR 1.56 [1.13, 2.15] | 7 studies · 1511 participants | Low Downgraded: risk of bias, publication bias |
RISPERIDONE + CLOZAPINE compared to PLACEBO + CLOZAPINE for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: no clinically significant response in psychotic symptoms ‐ short term PANSS/BPRS < 20% decline RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE | RR 1.15 [0.93, 1.42] | 2 studies · 98 participants | Low Downgraded: risk of bias, imprecision |
Leaving the study early due to any reason ‐ short term RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE | 1.13 [0.53, 2.42] | 3 studies · 167 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Global state: no significant clinical improvement ‐ CGI short term RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE | RR 1.12 [0.87, 1.44] | 1 study · 68 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: extrapyramidal ‐ short term RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE | no estimate extracted | NR | No studies |
Risperidone vs placebo
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early Risperidone vs placebo | RR 0.7 [0.57, 0.86] | 11 studies · 1363 participants | Very low Downgraded: risk of bias |
Global effect: No substantial change (CGI severity) Risperidone vs placebo | RR 0.8 [0.55, 1.15] | 3 studies · 397 participants | Very low Downgraded: risk of bias |
Mental state: No 20% response (as defined by PANSS/BPRS total change) Risperidone vs placebo | RR 0.7 [0.62, 0.79] | 7 studies · 856 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse event: Extrapyramidal ‐ significant EPS Risperidone vs placebo | RR 1.4 [0.93, 2.1] | 3 studies · 376 participants | Very low Downgraded: risk of bias |